GeneDx Holdings Corp. (WGS)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$85.99-1.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Broken: Primary pillar broken — Achieve positive adjusted net income in 2026: GAAP EPS -0.60 vs consensus -0.19.
GeneDx aims to grow revenue to about $482.5M in 2026 despite recent cuts. The company targets a gross margin near 70.5% and positive adjusted net income by year-end. New leadership and focus on exome and genome revenue support recovery. Analysts expect 22% revenue growth next year.
Recent earnings missed and guidance cuts show execution challenges. Revenue guidance was lowered from $540-$555M to $475-$490M. The company remains loss-making with elevated risk and a high price-to-earnings ratio near 77. Market doubts on turnaround progress persist.
The stock price is about 4% above our fair value near $63, reflecting roughly 22% revenue growth expected by analysts. Our fair value is 16% below the Street median, indicating some caution versus optimistic Street targets.
Breaks if: exome and genome revenue growth stalls or declines next year
Breaks if: gross margin falls below 65% in FY25
Breaks if: adjusted net income remains negative through FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario. WGS is currently loss-making but has shown some progress in adjusted profitability and revenue growth, although recent performance has been weak.
The market appears to have priced in a level of fragility due to WGS's expensive valuation compared to peers. There is an expectations gap, indicating that investors may be anticipating better performance than what has been delivered recently.
Management is focused on achieving positive adjusted net income and has made progress in revenue growth, particularly in exome and genome testing. However, the overall financial performance remains weak, and risks are elevated, especially with potential guidance cuts.
The future of WGS depends on several factors, including the company's ability to maintain or improve its guidance, the performance of key sector peers, and broader economic conditions that could impact demand in the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss is a significant concern. This miss indicates that the company is not achieving its financial targets. The overall market backdrop has also shifted to a risk-off sentiment.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Deliver adjusted net income profitability for full year 2026 while managing growth and operational expenses.
Stated as a priority in 3 of last 3 quarters. Adjusted net income improved from a loss of $8.2 million in 2026-Q1 to a positive $0.4 million in 2026-Q2, while GAAP net loss remains but adjusted results show progress. Management reiterated positive adjusted net income guidance for full year 2026. The trajectory is delivering with improving adjusted profitability.
“Successfully navigated our return to profitability with adjusted net income of $0.4 million.”
“Poised to deliver profitability on an adjusted basis for the year.”
“Reaffirmed full year 2026 guidance including positive adjusted net income.”
Breaks if: revenue falls below $475M in FY26
In the next 1 to 3 years, WGS's performance will be closely tied to its execution on management priorities and external market conditions. Not investment advice.